Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORA102 + Avastin in Neovascular AMD
NCT00745511Phase 2Unknown
- Sponsor
- Ora Bio Ltd
- Start
- Mar 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ORA102 in neovascular age-related macular degeneration (NVAMD), sponsored by Ora Bio Ltd. Status: unknown.
02
Drugs
ORA102
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00745511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00745511.